Beachbody (BODI) Q1 2026 Earnings Transcript

Beachbody reported Q1 revenue of $54.3 million, above the high end of guidance, with $2.3 million in net income, $3.1 million in operating income, and $8.0 million in adjusted EBITDA for the third, third, and tenth consecutive profitable periods on those metrics, respectively. Gross margin held at 71.8%, but revenue still fell 25% year over year and Q2 guidance calls for $46 million to $51 million in revenue and net income from negative $3 million to breakeven. Management highlighted a strategic shift to omnichannel nutrition, new retail distribution at Sprouts, Vitamin Shoppe, and KeHE, and a Southern California energy drink test market, but near-term comparables remain distorted by the wind-down of legacy MLM revenue.

Analysis

The key inflection is not the quarter’s profitability; it’s the change in customer acquisition economics. By shifting lead generation from digital fitness to nutrition, BODI is using a much larger intent pool to harvest lower CAC and higher basket sizes, while digital becomes the monetization layer rather than the entry point. That matters because it can stabilize revenue even if subscriptions remain soft, and it also makes the business less dependent on a single product cycle.

The second-order winner here is the distribution stack: Sprouts, Vitamin Shoppe, KeHE, Shopify, Advantage Solutions, and 3PLs all benefit from a small brand with meaningful awareness trying to punch above its weight in shelf placement. The hidden loser is legacy DTC/affiliate-style acquisition economics in the category; if BODI proves it can convert retail buyers into app users, competitors that rely on one-channel funnels will be forced to spend more to defend the same customer.

The market should be careful not to extrapolate the margin structure too aggressively. Retail and wholesale can expand volume, but they also dilute mix and increase inventory/working-capital complexity, so the next two quarters are more about proof of demand than margin expansion. The biggest near-term catalyst is not Q2 guidance; it’s the late-summer shelf read and whether the Southern California beverage test produces measurable retailer re-orders ahead of 2027 planograms.

Contrarian view: consensus may be underestimating how much of this is a database monetization story, not a pure turnaround story. If the nutrition-first funnel reactivates the installed base, BODI can grow without a proportional increase in fixed costs, which supports the equity despite modest top-line declines. But if retail velocity disappoints or inventory adjustments repeat, the whole thesis reverts to a low-growth, highly promotional consumer brand with limited cash cushion.

Key Decisions for Investors

• Long BODI common as a tactical 3-6 month event trade into late-summer retail shelf reads; upside comes from multiple expansion if KeHE/Vitamin Shoppe doors translate into reorder data, but trim quickly if Q2 cash burn worsens.
• Buy BODI Jan-2027 call spreads to express the 2027 planogram optionality with defined risk; the setup is favorable if the beverage test and retail rollout become credible over the next 2 quarters.
• Pair trade: long SFM vs short a basket of legacy DTC fitness/nutrition names over the next 6-12 months; SFM captures incremental shelf traffic while BODI’s success validates natural-channel expansion and pressures weaker entrants.
• Avoid chasing SHOP on this print; the upside from a single small merchant migration is already in the story, and any customer-conversion disappointment would hit the narrative before it hits Shopify economics.
• If long BODI, hedge with short-dated puts into the next earnings window; the stock is vulnerable to any inventory or cash-flow miss because the market will likely focus on liquidity, not adjusted EBITDA.